Clinical trial / 2013
Oral yeast-derived β-(1-3) glucan increased salivary lysozyme and CRP and improved general conditions in children with chronic respiratory problems.
A placebo-driven clinical trial evaluated the effects of a 100 mg/d oral dose of yeast-derived β-(1-3) glucan in 40 children aged 8-12 years with chronic respiratory problems. Researchers measured salivary levels of albumin, lysozyme, and CRP. Glucan treatment resulted in a significant increase in the production of lysozyme and CRP, along with a strong improvement in general conditions.
- Study type
- Placebo-driven clinical trial
- Who was studied
- 40 children aged 8-12 years with chronic respiratory problems
- What was measured
- Salivary levels of albumin, lysozyme, and CRP; general conditions
THE PAPER
Placebo-driven clinical trials of yeast-derived β-(1-3) glucan in children with chronic respiratory problems.
Vetvicka V, Richter J, Svozil V, Rajnohová Dobiášová L, Král V. Ann Transl Med, 2013.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.